Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 3.12% is 36% above its 5-year average of 2.30%, near the high end of its 5-year range (0.51%–3.32%).
2.19% below its 12-month average of 3.19%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.88%.
RETURN ON ASSETS (ROA)
3.12%
RETURN ON ASSETS (ROA) AVG TTM
3.19%
RETURN ON ASSETS (ROA) AVG 3Y
2.54%
RETURN ON ASSETS (ROA) AVG 5Y
2.30%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.19%
CURRENT VS 3Y AVG
+22.83%
CURRENT VS 5Y AVG
+35.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+109.67%
vs the sector median at left
The Pennant Group, Inc.
Market Cap
$1.39B
Return on Assets (ROA)
3.12%
TTM Avg
3.19%
3Y Avg
2.54%
5Y Avg
2.30%
Market Cap
$1.40B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Return on Assets (ROA)
-21.52%
TTM Avg
-21.52%
3Y Avg
-21.52%
5Y Avg
-21.52%
Market Cap
$1.40B
Return on Assets (ROA)
-31.81%
TTM Avg
-43.72%
3Y Avg
-70.87%
5Y Avg
-63.61%
Market Cap
$1.37B
Return on Assets (ROA)
-89.60%
TTM Avg
418.97%
3Y Avg
177.41%
5Y Avg
100.38%
Market Cap
$1.42B
Return on Assets (ROA)
61.75%
TTM Avg
-16.82%
3Y Avg
-22.73%
5Y Avg
-17.45%
Market Cap
$1.42B
Return on Assets (ROA)
-46.39%
TTM Avg
-37.70%
3Y Avg
-40.46%
5Y Avg
-33.71%
Market Cap
$1.34B
Return on Assets (ROA)
43.52%
TTM Avg
-28.82%
3Y Avg
-20.19%
5Y Avg
-30.60%
Market Cap
$1.44B
Return on Assets (ROA)
-4.89%
TTM Avg
-0.43%
3Y Avg
-0.87%
5Y Avg
-1.37%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.39B | 3.12% | 3.19% | 2.54% | 2.30% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | -21.52% | -21.52% | -21.52% | -21.52% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -31.81% | -43.72% | -70.87% | -63.61% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -89.60% | 418.97% | 177.41% | 100.38% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 61.75% | -16.82% | -22.73% | -17.45% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -46.39% | -37.70% | -40.46% | -33.71% |
| Omeros Corporation (OMER)vs › | $1.34B | 43.52% | -28.82% | -20.19% | -30.60% |
| Certara, Inc. (CERT)vs › | $1.44B | -4.89% | -0.43% | -0.87% | -1.37% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 14.98% | 6.07% | 5.42% | 6.72% |
ROA
3.1%
ROE
9.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.06% |
| 2024-12-31 | 3.32% |
| 2023-12-31 | 2.48% |
| 2022-12-31 | 1.30% |
| 2021-12-31 | 0.51% |
| 2020-12-31 | 3.11% |
| 2019-12-31 | 0.57% |
| 2018-12-31 | 15.98% |
| 2017-12-31 | 11.18% |
| 2016-12-31 | 0.00% |
